Top ▲
Gene and Protein Information | ||||||
Species | TM | AA | Chromosomal Location | Gene Symbol | Gene Name | Reference |
Human | - | 764 | 6p21.33 | CFB | complement factor B | |
Mouse | - | 761 | 17 18.41 cM | Cfb | complement factor B | |
Rat | - | 763 | 20p12 | Cfb | complement factor B |
Database Links | |
Specialist databases | |
MEROPS | S01.196 (Hs) |
Other databases | |
Alphafold | P00751 (Hs), P04186 (Mm) |
BRENDA | 3.4.21.47 |
CATH/Gene3D | 3.40.50.410 |
ChEMBL Target | CHEMBL5731 (Hs), CHEMBL4630808 (Mm) |
Ensembl Gene | ENSG00000243649 (Hs), ENSMUSG00000090231 (Mm), ENSRNOG00000051235 (Rn) |
Entrez Gene | 629 (Hs), 14962 (Mm), 294257 (Rn) |
Human Protein Atlas | ENSG00000243649 (Hs) |
KEGG Enzyme | 3.4.21.47 |
KEGG Gene | hsa:629 (Hs), mmu:14962 (Mm), rno:294257 (Rn) |
OMIM | 138470 (Hs) |
Orphanet | ORPHA158379 (Hs) |
Pharos | P00751 (Hs) |
RefSeq Nucleotide | NM_001710 (Hs), NM_212466 (Rn) |
RefSeq Protein | NP_001701 (Hs), NP_997631 (Rn) |
UniProtKB | P00751 (Hs), P04186 (Mm) |
Wikipedia | CFB (Hs) |
Enzyme Reaction | ||||
|
Download all structure-activity data for this target as a CSV file
Inhibitors | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Key to terms and symbols | View all chemical structures | Click column headers to sort | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Immunopharmacology Comments |
A protease component of the alternative complement pathway. Cleaved by complement factor D into a non-catalytic and catalytic fragment (Ba and Bb respectively). |
Immuno Process Associations | ||
|
||
|
Clinically-Relevant Mutations and Pathophysiology | ||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||
|
1. Gold B, Merriam JE, Zernant J, Hancox LS, Taiber AJ, Gehrs K, Cramer K, Neel J, Bergeron J, Barile GR et al.. (2006) Variation in factor B (BF) and complement component 2 (C2) genes is associated with age-related macular degeneration. Nat Genet, 38 (4): 458-62. [PMID:16518403]
2. Mainolfi N, Ehara T, Karki RG, Anderson K, Mac Sweeney A, Liao SM, Argikar UA, Jendza K, Zhang C, Powers J et al.. (2020) Discovery of 4-((2S,4S)-4-Ethoxy-1-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)piperidin-2-yl)benzoic Acid (LNP023), a Factor B Inhibitor Specifically Designed To Be Applicable to Treating a Diverse Array of Complement Mediated Diseases. J Med Chem, 63 (11): 5697-5722. [PMID:32073845]
3. Ruiz-Gómez G, Lim J, Halili MA, Le GT, Madala PK, Abbenante G, Fairlie DP. (2009) Structure-activity relationships for substrate-based inhibitors of human complement factor B. J Med Chem, 52 (19): 6042-52. [PMID:19743866]
S1: Chymotrypsin: complement factor B. Last modified on 03/03/2020. Accessed on 02/11/2024. IUPHAR/BPS Guide to PHARMACOLOGY, https://www.guidetoimmunopharmacology.org/GRAC/ObjectDisplayForward?objectId=2339.